Betta Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jan '22 Jan 1, 2022
Cash & Equivalents	421.01	429.98	471.68	752	731.28	791.99
Trading Asset Securities	89.23	66	126.44	0.54	-	201.01
Cash & Short-Term Investments	510.23	495.98	598.12	752.54	731.28	993
Cash Growth	-14.64%	-17.08%	-20.52%	2.91%	-26.36%	-35.35%
Accounts Receivable	512.46	351.26	98.47	286.41	450.62	173.38
Other Receivables	20.47	77.95	1.83	2.61	49.7	40.75
Receivables	532.93	429.21	100.3	289.02	500.32	214.13
Inventory	351.68	381.16	290.09	327.5	372.17	293.32
Prepaid Expenses	-	-	-	0.2	-	-
Other Current Assets	275.64	271.48	235.82	156.62	129.06	153.49
Total Current Assets	1,670	1,578	1,224	1,526	1,733	1,654
Property, Plant & Equipment	2,926	2,962	3,009	2,574	2,056	1,331
Long-Term Investments	2,539	2,583	1,437	1,382	919.27	345.79
Goodwill	413.58	413.58	413.58	413.58	413.58	413.58
Other Intangible Assets	2,749	2,604	2,776	1,944	1,219	1,183
Long-Term Accounts Receivable	-	13.28	9.29	-	-	-
Long-Term Deferred Tax Assets	59.48	59.13	56.73	39.13	85.96	55.06
Long-Term Deferred Charges	227.04	220.16	383.53	1,219	1,444	1,252
Other Long-Term Assets	103.4	133	32.7	50.3	39.3	37.6
Total Assets	10,688	10,566	9,342	9,147	7,910	6,271
Accounts Payable	417.94	512.32	746.11	800.12	35.85	431.19
Accrued Expenses	90.65	390.16	285.53	357.82	419.11	357.02
Short-Term Debt	5.03	5	100.08	300.27	380.39	-
Current Portion of Long-Term Debt	801.39	824.19	639.85	301.25	-	-
Current Portion of Leases	-	46.65	33.03	4.6	4.16	4.88
Current Income Taxes Payable	94.9	47.24	4.26	0.07	0.04	10.68
Current Unearned Revenue	5.31	2.37	2.63	4.92	4.46	0.69
Other Current Liabilities	271.21	89.36	36.47	34.11	1,261	84.4
Total Current Liabilities	1,686	1,917	1,848	1,803	2,105	888.86
Long-Term Debt	1,703	1,524	1,552	1,816	656.03	-
Long-Term Leases	51.21	62.84	71.63	8.18	7.3	6.34
Long-Term Unearned Revenue	184.36	226.22	150.99	144.7	112.76	112
Long-Term Deferred Tax Liabilities	162.49	167.91	53.49	23.39	71.57	68.39
Other Long-Term Liabilities	37.74	-	-	-	-	510.06
Total Liabilities	3,826	3,898	3,676	3,795	2,952	1,586
Common Stock	420.73	420.73	418.49	418.49	417.47	415.39
Additional Paid-In Capital	2,168	2,164	2,076	2,142	1,860	1,932
Retained Earnings	3,292	3,056	2,834	2,503	2,181	2,139
Comprehensive Income & Other	914.47	954.47	245.21	188.3	390.99	74.64
Total Common Equity	6,795	6,595	5,574	5,251	4,849	4,561
Minority Interest	67.78	72.53	92.3	100.4	108.64	124.9
Shareholders' Equity	6,863	6,668	5,666	5,351	4,958	4,686
Total Liabilities & Equity	10,688	10,566	9,342	9,147	7,910	6,271
Total Debt	2,561	2,462	2,396	2,430	1,048	11.22
Net Cash (Debt)	-2,051	-1,966	-1,798	-1,678	-316.59	981.77
Net Cash Growth	-	-	-	-	-	-35.97%
Net Cash Per Share	-4.89	-4.70	-4.29	-4.00	-0.76	2.36
Filing Date Shares Outstanding	420.73	420.73	418.49	418.49	417.47	415.39
Total Common Shares Outstanding	420.73	420.73	418.49	418.49	417.47	415.39
Working Capital	-15.94	-339.45	-623.63	-277.28	-371.95	765.08
Book Value Per Share	16.15	15.68	13.32	12.55	11.62	10.98
Tangible Book Value	3,632	3,577	2,384	2,894	3,216	2,964
Tangible Book Value Per Share	8.63	8.50	5.70	6.92	7.70	7.14
Buildings	-	3,041	2,952	586.14	585.59	627.19
Machinery	-	461.18	449.64	424.26	402.25	376.01
Construction In Progress	-	227.31	191.87	2,037	1,448	639.67

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.